Efficacy and Safety of Doravirine in the Rapid Initiation

Exclusion Criteria

• •1. History of hypersensitivity to doravirine, tenofovir, or lamivudine.
• •2. Severe hepatic impairment (Child-Pugh C).
• •3. Active HCV infection requiring specific treatment during study participation at the time of eligibility assessment. If HCV is diagnosed during the study and the participant requires treatment, the decision on whether to continue in the study will be at the investigator's discretion.
• •4. A woman may be eligible to enter and participate in the study if she is not pregnant (confirmed by a negative urine pregnancy test at the time of screening/baseline). If the baseline visit is scheduled on a different day than the SCR, the urine pregnancy test will be repeated) or breastfeeding and if at least one of the following conditions applies:
• •1. Women without reproductive capacity, defined as premenopausal women with tubal ligation or hysterectomy, or documented bilateral oophorectomy; or as postmenopausal women with 12 months of spontaneous amenorrhea, and women ≥ 45 years of age without hormone replacement therapy.
• •2. Women with reproductive capacity who agree to adopt one of the contraceptive options in Appendix 2 for at least 30 days after the last dose of study medication and/or completion of the follow-up visit.
• •The chosen contraceptive method must be used consistently, according to the approved product label. All study participants must be advised on safer sex practices, including the use of effective barrier methods, and the choice of effective contraceptive method must be documented in the eCRF (Electronic Case Report Form).
• •5. The subject's general health status, in the investigator's oIPnion, interferes with the requirements of the study.
• •6. Has a diagnosis of an active opportunistic infection defining AIDS or a malignant neoplasm within 30 days prior to evaluation (except Kaposi's sarcoma with fewer than 10 skin lesions).
• •7. Is participating or has participated in a clinical study in the last 6 months.
• •8. Creatinine clearance (CrCl) ≤50 mL/min according to the Cockcroft-Gault equation.
• •9. Any verified Grade 4 abnormality (except liIPds: HDL, LDL, total cholesterol, triglycerides).
• •10. History or presence of allergy to study drugs or their components, or to drugs in their class.
• •11. Subjects taking any medication during the study, including over-the-counter medications and herbal preparations, without the approval of the study physician.
• •12. Mutations resistant to doravirine, 3TC, or TDF, according to the list described below:
• •DOR mutations (INNTI):
• •Doravirine (INNTI) Primary: the presence of one or more ART-resistant mutations will be grounds for exclusion.
• •Mutations: V106A/M, F227C/V, L234I, Y188L, Y318F, M230I/L. Secondary: the presence of one or more RAMs will be grounds for exclusion. Mutations: A98G, V108I, G190E, H221Y, P225H, F227L, P236L. Others: the presence of five or more RAMs will be grounds for exclusion. Mutations: V90I, L100I, K101E/H/P, K103N/R/S, V106I, I135T, Y181C/I/V, E138A/G/K/Q/R, V170F/T, G190A/Q/S, Y188C/H, F227I, V245E, K311R.
• •NRTI (TDF) Relevant mutations: Presence of one or more RAM Mutations: K65R, insertion 69, K70R/E, Q151M,
• •NRTI (3TC) Relevant mutation Presence of IM184V